# Gary J. Schiller

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gary-j-schiller/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,343 |
| Field | Acute Myeloid Leukemia Research |
| h-index | 72 |
| i10-index | 265 |
| Last Known Institution | APLA Health |
| OpenAlex ID | https://openalex.org/A5037299848 |
| ORCID iD | https://orcid.org/0000-0002-7508-3467 |
| Works | 735 |

## Researcher papers

- [Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma](https://scholariq.org/papers/oral-selinexor-dexamethasone-for-triple-class-refractory-multiple-myeloma/)
- [Outcome of Transplantation for Myelofibrosis](https://scholariq.org/papers/outcome-of-transplantation-for-myelofibrosis/)
- [Comparison of Preparative Regimens in Transplants for Children With Acute Lymphoblastic Leukemia](https://scholariq.org/papers/comparison-of-preparative-regimens-in-transplants-for-children-with-acute/)
- [High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia](https://scholariq.org/papers/high-dose-vincristine-sulfate-liposome-injection-for-advanced-relapsed-and/)

## Researcher topics

- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)
- [Acute Lymphoblastic Leukemia research](https://scholariq.org/topics/acute-lymphoblastic-leukemia-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [APLA Health](https://scholariq.org/institutions/apla-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.